Abstract:The phase III randomised BR.21 study demonstrated that in patients with relapsed advanced NSCLC, erlotinib (Tarceva®) improved survival and prolonged time to symptom deterioration compared with placebo (Shepherd et al. NEJM 2005;353:123-132). Erlotinib was well tolerated, with rash and diarrhoea the most common adverse events (AEs), both being generally mild to moderate in severity. The global, open-label TRUST study was initiated to provide erlotinib access to patients with advanced NSCLC. Data are reported here for the E/SE subgroup. Eligible patients with stage IIIB/IV NSCLC had failed previous chemotherapy for advanced disease (≤2 prior regimens) or were unsuitable for chemotherapy. Erlotinib was administered orally 150mg/day until disease progression or unacceptable toxicity. Dose reductions (50mg increments) were allowed as required. The NCI-CTC v3.0 was used to assess toxicities, including: incidence and grade of erlotinib-related rash; serious AEs (SAEs) and treatment-related SAEs; and AEs leading to treatment withdrawal. Other treatment-related AEs were reported if they were not included on a list of 15 pre-specified AEs in the study protocol (rash; pruritis; dry skin; diarrhea; nausea; vomiting; stomatitis; abdominal pain; fatigue; dyspnoea; cough; anorexia; infection; conjunctivitis; and keratoconjunctivitis sicca). 885 patients were included in the analysis at the data cut-off (20/11/06) from Taiwan (n=297), mainland China (n=248), Hong Kong (n=160), South Korea (n=146), Thailand (n=30), Indonesia (n=2) and Malaysia (n=2). The median age was 61 years (range 22-95). Patient characteristics included: male 55%, female 45%; stage IIIB 20%, stage IV 79% (no data 1%); ECOG PS 0 15%, PS 1 67%, PS 2 14%, PS 3 4%; non-smoker 52%, ever-smoker 47% (no data <1%); adenocarcinoma 68%, squamous-cell carcinoma 19%, other 13%; erlotinib 1st line 11%, 2nd line 55%, 3rd line 33%, other <1%. Data on the occurrence of rash were available for 882 patients, 83% of whom experienced rash, mostly grade 1/2 (88% of those with rash). Adverse event (AE) safety data were available for 598 patients, 54% of whom experienced at least one AE. 19 patients (3%) had treatment-related SAEs, most commonly gastrointestinal (GI) disorders (1%), including abdominal pain (n=2), diarrhoea (n=5) and gastric ulcer haemorrhage (n=1). 17% of patients had at least one other treatment-related AE that was not pre-specified (3% had at least one grade 3/4 event); mucosal inflammation occurred in 3% of patients (<1% grade 3/4), but no other single event occurred in more than 2% of patients. Treatment-related interstitial lung disease (ILD; grade 2) was suspected in one patient, but this event was not reported as an SAE and did not lead to treatment withdrawal; the patient continued on erlotinib until disease progression. 18 patients (3%) had at least one treatment-related AE leading to withdrawal of erlotinib; the most common such events were rash (4 patients), diarrhoea (3 patients) and pneumonitis (3 patients). Among 589 patients with available data, 76 (13%) required dose reduction due to a treatment-related event, mainly rash (n=57). Efficacy data will be presented. Safety data for the E/SE Asian patient population in TRUST support the safety profile of erlotinib seen in clinical trials. The incidence of ILD and ILD-like events is <1%, which is in-keeping with what has been seen with erlotinib universally. In the‘real-life’ clinical setting, erlotinib is well tolerated, with full therapeutic doses administered to the majority of patients.

PD3-2-6: Interim Safety Results from the East/South East (E/SE) Asian Subgroup of the Open-Label TRUST (tarceva Lung Cancer Survival Treatment) Study of Erlotinib for Advanced Non-Small-cell Lung Cancer (NSCLC)

Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.

Safety and Efficacy of Abivertinib (AC0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M Positive Non-Small Cell Lung Cancer (NCSLC).

Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer

CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non–small cell lung cancer.

Third-line Treatment: A Randomized, Double-Blind, Placebo-Controlled Phase III ALTER-0303 Study—efficacy and Safety of Anlotinib Treatment in Patients with Refractory Advanced NSCLC.

P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study.

Efficacy and Safety of Befotertinib (D-0316) in Patients with EGFR T790M-Mutated NSCLC That Had Progressed after Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.

A Modified Phase 1 Clinical Trial of Abivertinib (ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer

Phase 3 Study of First-Line Crizotinib Vs Pemetrexed−cisplatin/carboplatin (PCC) in East Asian Patients (pts) with ALK+ Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC).

Erlotinib Versus Gemcitabine Plus Cisplatin As Neoadjuvant Treatment of Stage IIIA-N2 EGFR-mutant Non-Small-cell Lung Cancer: Final Overall Survival Analysis of the EMERGING-CTONG 1103 Randomised Phase II Trial

Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study

Open, Single Arm Trial of Erlotinib As the 2nd/3rd Line Treatment in Advanced or Recurrent Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Wild Type and C-Met Negative Expression (ml28941, C-Tong 1306)

Epidermal Growth Factor Receptor (egfr) and Abcg2 Polymorphisms and Treatment Outcome in the Randomized Phase III Torch Trial in Advanced Non-Small Cell Lung Cancer (nsclc) Patients

P3.01-036 A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis

P2.01-99 A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naïve Patients with EGFR Mutation-Positive NSCLC: Final Analysis

A Randomized Placebo-Controlled Phase III Study of Intercalated Erlotinib with Gemcitabine/platinum in First-Line Advanced Non-Small Cell Lung Cancer (NSCLC): FASTACT-II.

Final Overall Survival Results from a Randomised, Phase III Study of Erlotinib Versus Chemotherapy As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-cell Lung Cancer (OPTIMAL, CTONG-0802).

The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC).

Erlotinib Versus Etoposide/Cisplatin with Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial